Berdazimer sodium

Berdazimer sodium
Clinical data
Trade namesZelsuvmi
Other namesSB206
License data
Routes of
administration		Topical
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaIndeterminate[1]
Molar mass Indeterminate[1]

Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum.[1] Berdazimer sodium is a nitric oxide releasing agent.[1] It is a polymer formed from sodium 1-hydroxy-3-methyl-3-(3-(trimethoxysilyl)propyl)-1-triazene-2-oxide and tetraethyl silicate.[2]

Berdazimer sodium was approved for medical use in the United States in January 2024.[3][4][5]

Medical uses

Berdazimer sodium is indicated for the topical treatment of molluscum contagiosum.[1]

Warnings and Precaustions

Application site reactions, including allergic contact dermatitis, have occurred in patients treated with Zelsuvmi (Berdazimer sodium). Suspect allergic contact dermatitis in the event of pain, pruritus, swelling or erythema at the application site lasting longer than 24 hours. If allergic contact dermatitis occurs, discontinue ZELSUVMI and initiate appropriate therapy.

Mechanism of Action

Berdazimer sodium is a nitric oxide releasing agent. The mechanism of action for the treatment of molluscum contagiosum is unknown.

Society and culture

Berdazimer sodium was approved for medical use in the United States in January 2024.[4]

Names

Berdazimer sodium is the international nonproprietary name.[6]

References

  1. 1 2 3 4 5 6 "Zelsuvmi (berdazimer) topical gel" (PDF). Archived (PDF) from the original on 19 January 2024. Retrieved 9 January 2024.
  2. ↑ "GSRS". gsrs.ncats.nih.gov. Archived from the original on 8 January 2024. Retrieved 8 January 2024.
  3. ↑ "Drug Approval Package: Zelsuvmi". U.S. Food and Drug Administration (FDA). 2 February 2024. Archived from the original on 11 March 2024. Retrieved 11 March 2024.
  4. 1 2 "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 5 January 2024. Archived from the original on 8 January 2024. Retrieved 8 January 2024.
  5. ↑ "U.S. Food and Drug Administration Approves Zelsuvmi as a First-in-Class Medication for the Treatment of Molluscum Contagiosum". Ligand Pharmaceuticals. 5 January 2024. Archived from the original on 8 January 2024. Retrieved 8 January 2024 – via Business Wire.
  6. ↑ World Health Organization (2018). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 79". WHO Drug Information. 32 (1). hdl:10665/330941.

Further reading


This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.